Q2 Earnings Estimate for RYTM Issued By HC Wainwright

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.40) for the quarter. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

RYTM has been the topic of a number of other reports. Canaccord Genuity Group increased their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Stifel Nicolaus began coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a “buy” rating and a $78.00 price target on the stock. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective for the company. The Goldman Sachs Group boosted their target price on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Finally, JMP Securities reiterated a “market outperform” rating and set a $75.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.46.

Rhythm Pharmaceuticals Trading Down 1.5 %

NASDAQ:RYTM opened at $52.91 on Tuesday. The company has a market cap of $3.35 billion, a price-to-earnings ratio of -12.22 and a beta of 2.30. Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The stock has a fifty day simple moving average of $55.28 and a 200-day simple moving average of $54.99.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The firm had revenue of $41.83 million during the quarter, compared to analysts’ expectations of $38.48 million.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RYTM. Victory Capital Management Inc. lifted its stake in shares of Rhythm Pharmaceuticals by 158.0% in the third quarter. Victory Capital Management Inc. now owns 18,186 shares of the company’s stock worth $953,000 after acquiring an additional 11,137 shares in the last quarter. Intech Investment Management LLC bought a new position in Rhythm Pharmaceuticals in the 3rd quarter worth about $649,000. Charles Schwab Investment Management Inc. increased its position in Rhythm Pharmaceuticals by 1.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,866 shares of the company’s stock valued at $22,730,000 after acquiring an additional 5,908 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Rhythm Pharmaceuticals during the third quarter valued at $1,313,000. Finally, Loomis Sayles & Co. L P bought a new stake in shares of Rhythm Pharmaceuticals during the 3rd quarter worth about $33,353,000.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 1,281 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $76,129.83. Following the transaction, the insider now owns 2,657 shares of the company’s stock, valued at $157,905.51. This trade represents a 32.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Christopher Paul German sold 635 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total transaction of $36,334.70. Following the sale, the chief accounting officer now directly owns 2,070 shares of the company’s stock, valued at approximately $118,445.40. This trade represents a 23.48 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 108,131 shares of company stock valued at $5,781,098. 5.60% of the stock is owned by corporate insiders.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.